Abstract
Permanent loss of cardiomyocytes after ischemic injury often initiates the development of heart failure and adversely affects clinical outcome. The concept of progenitor-cell transfer for enhancing cardiac repair has raised new therapeutic prospects. Promising results have been reported in early studies in rodents, using various modalities of progenitor-cell transfer in the dysfunctional heart, although underlying mechanisms remain ill defined. Despite ongoing controversies over whether or not stem cells can autonomously adapt cardiomyocyte-like behavior after genetic reprogramming or whether they merely fuse with native host cardiomyocytes, early-phase clinical trials have shown a reassuring safety profile and suggest a functional benefit. However, identification of the intrinsic value of stem cell transfer in patients after myocardial infarction will require carefully designed randomized, placebo-controlled, blinded studies. While these are becoming available, a number of critical questions about the choice of progenitor-cell type, dosage regimen, and timing of administration need to be considered, and end points for future clinical trials need to be chosen carefully. There is great enthusiasm for this novel treatment paradig...Continue Reading
References
May 10, 2000·Circulation·L Reinlib, L Field
Jun 14, 2000·Circulation·B L GerberJ A Lima
Jun 28, 2000·Circulation·M G Sutton, N Sharpe
Apr 5, 2001·Nature·D OrlicP Anversa
Jun 8, 2001·The Journal of Clinical Investigation·K A JacksonM A Goodell
Mar 29, 2002·The New England Journal of Medicine·Gregg W StoneUNKNOWN Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators
Oct 9, 2002·Circulation·Bodo E StrauerPeter Wernet
Dec 11, 2002·Circulation·Birgit AssmusAndreas M Zeiher
Jun 5, 2003·Nature Medicine·Shahin Rafii, David Lyden
Oct 8, 2003·Proceedings of the National Academy of Sciences of the United States of America·Hidemasa OhMichael D Schneider
Oct 14, 2003·Nature·Manuel Alvarez-DoladoArturo Alvarez-Buylla
Nov 12, 2003·The New England Journal of Medicine·Marc A PfefferUNKNOWN Valsartan in Acute Myocardial Infarction Trial Investigators
Mar 23, 2004·Nature·Charles E MurryLoren J Field
Mar 23, 2004·Nature·Leora B BalsamRobert C Robbins
Apr 27, 2004·Nature Medicine·Jens M NygrenSten Eirik W Jacobsen
Jul 13, 2004·Lancet·Kai C WollertHelmut Drexler
Dec 1, 2004·Circulation Research·Jan KajsturaPiero Anversa
Jan 14, 2005·Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance·C Joon ChoiChristopher M Kramer
Feb 17, 2005·European Heart Journal·Vinzenz HombachHans A Kestler
Mar 9, 2005·Circulation·Jane A Leopold, Elliott M Antman
Apr 7, 2005·Nature Medicine·Massimiliano GnecchiVictor J Dzau
Jul 7, 2005·Circulation·Wangde DaiRobert A Kloner
Sep 2, 2005·The European Respiratory Journal·N MilmanM Iversen
Jan 18, 2006·Lancet·Stefan JanssensFrans Van de Werf
Citations
Oct 13, 2006·Antioxidants & Redox Signaling·Nikolaos G Frangogiannis
Jul 26, 2008·Human Gene Therapy·Barbara GuinnMark Tangney
Feb 25, 2009·Heart Failure Reviews·Heming WeiWinston Shim
Jun 19, 2010·Journal of Cardiovascular Translational Research·Mariann GyöngyösiGerald Maurer
Oct 9, 2007·European Radiology·Yuxiang Ye, Jan Bogaert
Aug 21, 2007·Expert Opinion on Biological Therapy·Beatriz PelachoFelipe Prósper
Nov 2, 2011·Cytotherapy·Yerem YeghiazariansHarold S Bernstein
Apr 9, 2008·Journal of Molecular and Cellular Cardiology·Victoria L T Ballard, Jay M Edelberg
Mar 25, 2008·Experimental Hematology·Silvia CharwatDietmar Glogar
Aug 27, 2009·Transfusion Medicine·E Martin-RendonS M Watt
Feb 13, 2009·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Ran Kornowski
Dec 18, 2012·European Journal of Heart Failure·Thomas Eschenhagen
Nov 13, 2008·Nature Clinical Practice. Cardiovascular Medicine·Mariann GyöngyösiDietmar Glogar